Literature DB >> 8646510

Cranial irradiation after surgical excision of brain metastases in melanoma patients.

J M Skibber1, S J Soong, L Austin, C M Balch, R E Sawaya.   

Abstract

BACKGROUND: Brain metastases account for 20-54% of reported deaths from melanoma. Duration and quality of survival depend on the extent of metastatic disease and response to treatment. Treatment goals are palliation of symptoms and prolongation of life. No studies have directly compared surgery alone and surgery with adjunctive cranial irradiation in patients with solitary brain metastases.
METHODS: We evaluated postoperative adjunctive cranial irradiation in 34 patients with solitary brain metastases.
RESULTS: Overall survival was significantly improved in the 22 patients who received adjunctive cranial irradiation versus that in the 12 patients who had surgery alone. Twenty-eight patients subsequently relapsed. Nine of 10 patients with surgery alone had brain recurrence as a component of failure. Six of 10 patients not receiving irradiation had brain recurrences as a component of relapse at multiple sites whereas only 1 of 18 patients receiving irradiation relapsed with the brain.
CONCLUSIONS: Adjunctive cranial irradiation is justified for melanoma patients who undergo surgical therapy for solitary brain metastases. Survival in patients presenting with solitary brain metastases was improved by a reduction of relapse in the brain as a component of failure by combined surgery and irradiation.

Entities:  

Mesh:

Year:  1996        PMID: 8646510     DOI: 10.1007/bf02305789

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

1.  Brain scans, dexamethasone therapy, and brain tumors.

Authors:  J W Fletcher; E A George; R E Henry; R M Donati
Journal:  JAMA       Date:  1975-06-23       Impact factor: 56.272

2.  The role of postoperative radiotherapy after resection of single brain metastases.

Authors:  L M DeAngelis; L R Mandell; H T Thaler; D W Kimmel; J H Galicich; Z Fuks; J B Posner
Journal:  Neurosurgery       Date:  1989-06       Impact factor: 4.654

3.  Management of solitary melanoma metastasis of the brain.

Authors:  E P Guazzo; R L Atkinson; M Weidmann; D J Effeney
Journal:  Aust N Z J Surg       Date:  1989-04

4.  Intracranial metastatic malignant melanoma: long-term survival following subtotal resection.

Authors:  M L Bauman; T R Price
Journal:  South Med J       Date:  1972-03       Impact factor: 0.954

5.  Long-term survival with recurrent metastatic intracranial melanoma. Case report.

Authors:  D P McNeel; M E Leavens
Journal:  J Neurosurg       Date:  1968-07       Impact factor: 5.115

6.  Surgical treatment of brain metastases in malignant melanoma.

Authors:  K Brega; W A Robinson; K Winston; W Wittenberg
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

7.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

8.  Surgical treatment of single brain metastasis: factors associated with survival.

Authors:  J H Galicich; N Sundaresan; E Arbit; S Passe
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

9.  Radiotherapy of intracerebral metastatic malignant melanoma.

Authors:  J S Cooper; R Carella
Journal:  Radiology       Date:  1980-03       Impact factor: 11.105

Review 10.  Management of metastatic brain tumors.

Authors:  R Sawaya; B L Ligon; R K Bindal
Journal:  Ann Surg Oncol       Date:  1994-03       Impact factor: 5.344

View more
  33 in total

Review 1.  The evolving role of radiation therapy in the management of malignant melanoma.

Authors:  Niloufer Khan; Mohammad K Khan; Alex Almasan; Arun D Singh; Roger Macklis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

2.  Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases.

Authors:  Maximilian I Ruge; Martin Kocher; Mohammad Maarouf; Christina Hamisch; Harald Treuer; Jürgen Voges; Volker Sturm
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

3.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Authors:  Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; Tobias H Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna C Pavlick; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

4.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.

Authors:  Jonathan P S Knisely; James B Yu; Jaclyn Flanigan; Mario Sznol; Harriet M Kluger; Veronica L S Chiang
Journal:  J Neurosurg       Date:  2012-06-15       Impact factor: 5.115

Review 5.  Surgical management of brain metastases.

Authors:  J S Weinberg; F F Lang; R Sawaya
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

Review 6.  Neurosurgical management of patients with brain metastasis.

Authors:  Mustafa Aziz Hatiboglu; Kerime Akdur; Raymond Sawaya
Journal:  Neurosurg Rev       Date:  2018-07-29       Impact factor: 3.042

7.  Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Authors:  Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

8.  Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

Authors:  Rajendar K Mittapalli; Shruthi Vaidhyanathan; Arkadiusz Z Dudek; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2012-12-17       Impact factor: 4.030

Review 9.  Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Authors:  Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2016-10-22       Impact factor: 4.693

Review 10.  The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Steven N Kalkanis; Douglas Kondziolka; Laurie E Gaspar; Stuart H Burri; Anthony L Asher; Charles S Cobbs; Mario Ammirati; Paula D Robinson; David W Andrews; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Mark E Linskey
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.